Executive Interviews

1. State Of The Orphan Space 3/1/2024

   Inozyme's CEO and chairman Douglas Treco shares his thoughts about the rousing success of the Orphan Drug Act, but cautions rare disease drug developers against sky high and inaccessible drug pricing practices.

2. NORD Expands Advocacy And Support For Rare Disease Patients, And Industry 2/29/2024

   NORD's president and CEO, Peter Saltonstall, offers details on the organization's current activities and ongoing work with biopharmaceutical companies developing rare disease drugs.

3. No Playbook For Leqembi: Eisai's Long Game In Alzheimer's Disease 2/16/2024

   Paul Hawthorne, Eisai's EVP, purpose and chief business officer, offers insight into building a market for Leqembi, Eisai's pricing and commercial strategy, and the challenges and opportunities in Alzheimer's disease.

4. An Outsourcing Future Of Information Sharing And Commercial Streamlining 12/1/2023

   Outsourced Pharma Chief Editor Louis Garguilo writes about what outsourcing professionals think about the future of working with CDMOs.

5. Top 2024 Clinical Trial Site Challenges: Staffing & Technology 12/1/2023

   Industry experts talk about some of the new challenges facing clinical trial sites in 2024.

6. Executive Outlook: Converting Innovative Science Into Predictable Returns 12/1/2023

   Executives at Big Pharma and small biotech will be rewarded in 2024 if they can find new ways to develop and commercialize drugs in the context of an unforgiving investment, payer, and regulatory landscape.

7. Biopharma's Eminent Challenges In 2024 — Inside & Out 12/1/2023

   A baker’s dozen of biopharma CEOs answer a call to prioritize and describe challenges they expect to face in the coming year.

8. Defining A Competitive Next-Gen RNA Therapeutic In 2024 12/1/2023

   To start singling-out where the opportunities exist to craft the next generation of RNA therapeutics, Anna Rose Welch sat down with four RNA executives.

9. Finance And Funding: Anticipating Improvement, Planning For Uncertainty 12/1/2023

   Executives responding to this year’s finance and funding outlook questions are optimistic about the potential for a turnaround in 2024.

10. Moving Beyond AAV: The Next Generation Of Vectors In CGT 12/1/2023

    We catch up with Dr. Konstantin Konstantinov, CTO at Ring Therapeutics, and Ryan Crisman, Ph.D., cofounder and CTO at Umoja Biopharma, to get their thoughts on the future of new anellovirus vectors and existing lentiviral vector technology for in vivo gene delivery respectively.